US 11,851,492 B2
Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
Josef Straub, Seeheim-Jugenheim (DE); and Eike Staub, Darmstadt (DE)
Assigned to Merck Patent GmbH, Darmstadt (DE)
Filed by Merck Patent GmbH, Darmstadt (DE)
Filed on Mar. 14, 2022, as Appl. No. 17/654,801.
Application 17/654,801 is a continuation of application No. 16/518,174, filed on Jul. 22, 2019, granted, now 11,306,146.
Application 16/518,174 is a continuation of application No. 15/511,959, granted, now 10,435,472, issued on Oct. 8, 2019, previously published as PCT/EP2015/001701, filed on Aug. 18, 2015.
Claims priority of provisional application 62/051,525, filed on Sep. 17, 2014.
Prior Publication US 2022/0275094 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/09 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); G01N 33/574 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2848 (2013.01) [A61K 38/09 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); G01N 33/57484 (2013.01); G01N 33/57488 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/94 (2013.01); G01N 2800/52 (2013.01)] 16 Claims
 
1. A method of treating a bone metastasis disease in a subject, wherein said subject is characterized by:
a) a high level of a protein in at least one body fluid of said subject, wherein said protein is
ICAM3;
and/or
b) a low level of one or more proteins in at least one body fluid of said subject, wherein said one or more proteins are selected from the group consisting of:
MAP2K2, and
MAPK11;
said method comprising:
administering to said subject at least one pan αv integrin inhibitor, wherein said at least one pan αv integrin inhibitor comprises Abituzumab and/or Intetumumab;
wherein a level of a specific protein of said one or more proteins in at least one body fluid of said subject is
a) classified as high, if the level of the specific protein of said one or more proteins in said body fluid is at least 2% higher than a median threshold determined for the specific protein,
and/or
b) classified as low, if the level of the specific protein of said one or more proteins in said body fluid is at least 2% lower than said median threshold fir the specific protein; and
wherein a threshold or median threshold for the specific protein is determined from the body fluid of a plurality of subjects being part of a diseased subject population suffering from the bone metastasis disease.